Drug Profile
PF 6678552
Alternative Names: PF-06678552; PF-6678552Latest Information Update: 04 Sep 2014
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 07 Aug 2014 Discontinued - Phase-I for Hypercholesterolaemia (In volunteers) in Belgium (PO)
- 29 Jul 2014 Pfizer completes a phase I trial in Healthy volunteers in Belgium (NCT02079922)
- 01 Apr 2014 Pfizer initiates enrolment in a phase I trial in Healthy volunteers in Belgium (NCT02079922)